AnaBios offers its clients and partners full access to an extensive battery of assays and technologies that enable the study of ex-vivo human responses to drugs and the investigation of the molecular and functional basis of human physiology. AnaBios focuses primarily on ex-vivo human studies for cardiovascular safety, pain and neurodegeneration. AnaBios has a successful track record in employing its proprietary platform to support target selection and validation, lead optimization, clinical candidate selection and clinical program de-risking. AnaBios uses its technology to advance the development of drugs originally discovered in academia or pharmaceutical companies and subsequently out-licensed to AnaBios. These assets are advanced by AnaBios to the beginning of clinical stage. AnaBios typically in-licenses drug programs in the late pre-clinical stage and applies its technology to replace many traditional in vitro or animal studies with its modern human-focused approach, more predictive of the real safety and efficacy of drugs. This allows not only for the selection of better clinical candidates but also for the identification of the specific disease and drug dosing most appropriate for the drug.
Ex-vivo human tissue and cell based studies - cardiac and peripheral sensory neurons
Ex-vivo human tissue and cell based assays - cardiac and peripheral sensory neurons
AnaBios Corporation has not received any reviews.
AnaBios Corporation has not received any endorsements.